Close Menu

asset acquisition

The purchase provides Thermo Fisher with access to the $40 billion pharmaceutical contract development and manufacturing market.

Headed by Nuclea's former Founder and CEO Patrick Muraca, NanoMolecular aims to commercialize cancer diagnostics including Nuclea's Her2/neu assay.

The clinical genetics and genomics testing firm said the funding will help as it seeks to consolidate its presence in international markets.

The acquisition of GeneWorks' oligo business widens IDT's reach in the Asia-Pacific region, the company said.

CareDx's CareDx Pty subsidiary said it will pay up to $735,000 to Conexio as a percentage of revenues from products acquired in the deal. 

In addition to variant detection technology, Omicia also gets technologies like data compression, which will aid diagnostics development and data storage. 

The deal, completed this month with cash reserves for an undisclosed price, adds scalability and multi-omics analysis to Qiagen's bioinformatics portfolio.

Identigene sells in-home DNA paternity test collection kits, while DNA Diagnostics conducts DNA testing for various applications, such as paternity and forensics. 

Thermo Fisher said the deal strengthens its portfolio for stem cell research, and it will fold MTI-GlobalStem into its life sciences solutions segment.

The company purchased Tute in a stock-based transaction that closed last month.

Pages

A letter criticizing actions by the US government and research institutions toward Chinese and Chinese-American scientists has garnered more than a hundred signatories.

NPR reports that researchers in New York are investigating whether it is possible to edit the genomes of human sperm.

In an opinion piece at the Nation, Sarah Lawrence College's Laura Hercher argues that everyone should be able to access prenatal genetic testing.

In Nature this week: ancient DNA uncovers presence of Mediterranean migrants at a Himalayan lake, and more.